Pfizer hopes to launch its vaccine once morest RSV (respiratory syncytial virus), the cause of bronchiolitis, in the fall of 2023. revealed Le Figaro THURSDAY. The American laboratory is thus targeting pregnant women and the elderly. “We hope to have a green light in time to be able to deploy our vaccine from the next winter season,” Annaliesa Anderson, scientific manager of R&D for Pfizer’s vaccines division, told the daily.
The tests carried out by the research giant should soon be approved, Pfizer benefiting from “accelerated procedures in the United States and Europe”, specifies Annaliesa Anderson. The laboratory hopes for validation of the vaccine for seniors in May and for pregnant women next August.
A promising market
The bronchiolitis vaccine market might bring big profits to Pfizer. It is estimated at 10 billion dollars per year over the next ten years for the elderly and 3 billion for infants, indicates Capital. Enough to take over from the vaccine once morest Covid-19, the use of which might decline in the years to come. In 2022, sales of injections once morest the coronavirus had allowed Pfizer to collect 37.8 billion dollars.
Bronchiolitis, which causes babies to cough and have difficulty breathing, is usually not serious. But this season, it has caused an epidemic of an unprecedented scale for more than ten years in France. This outbreak put hospitals in difficulty, especially as it added to the successive waves of Covid, as well as the seasonal flu epidemic. About 50,000 hospitalizations per year are linked to bronchiolitis in France, most of which concern young children.
